Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-2,page-paged-2,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer
    03 May 2022
    www.destinypharma.com
  • Abivax publishes Universal Registration Document 2022 “Document d’Enregistrement Universel”
    28 April 2022
    www.abivax.com
  • Marinomed’s Australian Carragelose distribution network strengthened
    28 April 2022
    www.marinomed.com
  • Deutsches Herzzentrum München veröffentlicht erste Ergebnisse aus „Vroni-Studie“: Bayerische Pilotstudie identifiziert 76 Kinder mit bedrohlicher Cholesterinstörung
    27 April 2022
    www.dhm.mhn.de
  • Temedica wins further renowned industry representatives for expert advisory board
    26 April 2022
    www.temedica.com
  • ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
    26 April 2022
    www.vigeneron.com
  • Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis
    13 April 2022
    www.imcyse.com
  • Marinomed reports on strong 2021 financial year
    13 April 2022
    www.marinomed.com
  • Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
    12 April 2022
    www.secarna.com
  • Destiny Pharma plc: Audited results for the year ended 31 December 2021
    12 April 2022
    www.destinypharma.com